Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings.

Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due ...

Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Lots of stars are slimming down, igniting a Hollywood trend that raises concerns about the return of dangerous beauty standards.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...